Maze Therapeutics, Inc.
MAZE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $649 | $0 | $0 |
| Gross Profit | $0 | -$649 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $25,190 | $28,108 | $27,580 | $22,216 |
| G&A Expenses | $7,775 | $8,366 | $7,821 | $7,510 |
| SG&A Expenses | $7,775 | $8,366 | $7,821 | $7,510 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$649 | $0 | $0 |
| Operating Expenses | $32,965 | $35,825 | $35,401 | $29,726 |
| Operating Income | -$32,965 | -$36,474 | -$35,401 | -$29,726 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2,878 | $2,795 | $2,615 | -$128 |
| Pre-Tax Income | -$30,087 | -$33,679 | -$32,786 | -$29,854 |
| Tax Expense | $0 | $0 | $0 | -$275 |
| Net Income | -$30,087 | -$33,679 | -$32,786 | -$29,579 |
| % Margin | – | – | – | – |
| EPS | -0.66 | -0.77 | -0.749 | -0.112 |
| % Growth | 14.3% | -2.9% | -568.4% | – |
| EPS Diluted | -0.66 | -0.77 | -0.749 | -0.112 |
| Weighted Avg Shares Out | 45,780 | 43,851 | 43,797 | 43,796 |
| Weighted Avg Shares Out Dil | 45,780 | 43,851 | 43,797 | 43,796 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,878 | $2,795 | $2,615 | $1,516 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $571 | $649 | $684 | $705 |
| EBITDA | -$29,516 | -$33,030 | -$34,717 | -$29,021 |
| % Margin | – | – | – | – |